Welcome to DU!
The truly grassroots left-of-center political community where regular people, not algorithms, drive the discussions and set the standards.
Join the community:
Create a free account
Support DU (and get rid of ads!):
Become a Star Member
Latest Breaking News
General Discussion
The DU Lounge
All Forums
Issue Forums
Culture Forums
Alliance Forums
Region Forums
Support Forums
Help & Search
Study Shines a Light on Depression: much better than prozac or placebo
http://www.psychiatrictimes.com/major-depressive-disorder/study-shines-light-depression
Study Shines a Light on Depression
December 10, 2015
By Dee Rapposelli
RESEARCH
Light therapy may be an effective treatment for major depressive disorder (MDD), says a multicenter team of researchers. Lam and colleagues1 conducted the first adequate-duration, placebo-controlled, randomized clinical trial comparing light therapy with antidepressant monotherapy (fluoxetine hydrochloride 20 mg/d) and combination light/antidepressant therapy.
<snip>
Light monotherapy consisted of exposure to an active 10,000lux fluorescent white light box for 30 minutes every morning plus ingestion of a placebo pill. Fluoxetine monotherapy included use of an inactive ion generator, which served as a sham light box. Patients allocated to combination therapy received both fluoxetine 20 mg/d and active light therapy, and those allocated to placebo only received a placebo pill and underwent exposure to the inactive ion generator.
<snip>
More effective than fluoxetine alone
Light therapy, either as monotherapy or in combination with fluoxetine, was effective and well tolerated. Indeed, although combination therapy provided the most consistent effects, fluoxetine monotherapy was no more effective than placebo—although the researchers noted that the seemingly poor performance of fluoxetine monotherapy may have been a consequence of a smaller-than-planned sample size.
The mean change in MADRS score from baseline at 8 weeks was 16.9 (±9.2) in patients who received combination therapy, 13.4 (±7.5) in those who received light monotherapy, 8.8 (±9.9) in those who received fluoxetine monotherapy, and 6.5 (±9.6) in those who received placebo.
Response, defined as a 50% or more reduction from baseline in MADRS scores, was achieved by 76% of the group receiving combination therapy; 50% of the group receiving light monotherapy; 29% of those receiving fluoxetine monotherapy; and 30% of those receiving placebo. Remission, defined as a MADRS score of 10 or lower at the final visit, was achieved by 59% of the combination-therapy group, 44% of the light-monotherapy group, 19% of the fluoxetine-monotherapy group, and 30% of the placebo group. No significant differences in terms of adverse events were seen.
<snip>
Study Shines a Light on Depression
December 10, 2015
By Dee Rapposelli
RESEARCH
Light therapy may be an effective treatment for major depressive disorder (MDD), says a multicenter team of researchers. Lam and colleagues1 conducted the first adequate-duration, placebo-controlled, randomized clinical trial comparing light therapy with antidepressant monotherapy (fluoxetine hydrochloride 20 mg/d) and combination light/antidepressant therapy.
<snip>
Light monotherapy consisted of exposure to an active 10,000lux fluorescent white light box for 30 minutes every morning plus ingestion of a placebo pill. Fluoxetine monotherapy included use of an inactive ion generator, which served as a sham light box. Patients allocated to combination therapy received both fluoxetine 20 mg/d and active light therapy, and those allocated to placebo only received a placebo pill and underwent exposure to the inactive ion generator.
<snip>
More effective than fluoxetine alone
Light therapy, either as monotherapy or in combination with fluoxetine, was effective and well tolerated. Indeed, although combination therapy provided the most consistent effects, fluoxetine monotherapy was no more effective than placebo—although the researchers noted that the seemingly poor performance of fluoxetine monotherapy may have been a consequence of a smaller-than-planned sample size.
The mean change in MADRS score from baseline at 8 weeks was 16.9 (±9.2) in patients who received combination therapy, 13.4 (±7.5) in those who received light monotherapy, 8.8 (±9.9) in those who received fluoxetine monotherapy, and 6.5 (±9.6) in those who received placebo.
Response, defined as a 50% or more reduction from baseline in MADRS scores, was achieved by 76% of the group receiving combination therapy; 50% of the group receiving light monotherapy; 29% of those receiving fluoxetine monotherapy; and 30% of those receiving placebo. Remission, defined as a MADRS score of 10 or lower at the final visit, was achieved by 59% of the combination-therapy group, 44% of the light-monotherapy group, 19% of the fluoxetine-monotherapy group, and 30% of the placebo group. No significant differences in terms of adverse events were seen.
<snip>
2 replies
= new reply since forum marked as read
= new reply since forum marked as read
